Category overview

RadTech

Radiation therapy, radiosurgery, and radiation detection & dosimetry.

ARAYAccuray Incorporated

Radiosurgery & radiation therapy systems (CyberKnife, TomoTherapy)

Volume 765.6× the 20-day averageEstimated price 2305% above priceEstimate shown is the peer P/S-implied price, not the DCF: the discounted-cash-flow model is not meaningful for this name (negative terminal-year cash flow). Value it on relative multiples and Level-3 assumptions, not the raw DCF.

MIRMirion Technologies

Radiation detection, measurement & dosimetry

Price 28% above estimated priceDebt definitions conflict. Terminal facts show total debt of $444.8M against $418.7M cash — net leverage of roughly 0.14x, comfortably inside the 2.5x threshold. However the Q1 2026 10-Q discloses $1.23B of total debt including $775M of convertible notes; on that basis net debt of ~$811M against $189.6M TTM EBITDA implies ~4.3x, beyond the 3.5x escalation trigger. The $444.8M figure appears to track the term loan only (the 10-K references '$450 million in term loans plus convertible notes'). Reconcile the convert treatment — whether cash-settled, equity-classified, or simply excluded from the data feed — before treating this balance sheet as low-leverage; on the filing's own numbers this is a refinancing-sensitive story, not a fortress.

DRTSAlpha Tau Medical Ltd.

Estimated cash runway of ~3-4 months ($12.2M cash vs. -$42.3M TTM EBITDA) is far below the 24-month threshold for a pre-revenue name ahead of a value-inflection readout.

SRTSSensus Healthcare, Inc.

Estimate shown is the peer P/S-implied price, not the DCF: the discounted-cash-flow model is not meaningful for this name (negative enterprise value). Value it on relative multiples and Level-3 assumptions, not the raw DCF.Single-customer concentration far exceeds 40%: largest customer was 52% of FY2025 revenue (73% in 2024), and Q1 2026 booked no sales to that historically large U.S. customer; two U.S. customers were 25% and 24% of Q1 revenue. With FY2025 revenue down 34% to $27.5M and Q1 2026 down 59% to $3.4M at a 29.4% gross margin, the re-rating case depends on CMS SRT reimbursement (effective 1/1/2026) reviving demand from a very narrow buyer base — a credible threat to the concentration rather than a diversification.

ATNMActinium Pharmaceuticals, Inc.

Price 99% above estimated priceEstimate shown is the peer P/S-implied price, not the DCF: the discounted-cash-flow model is not meaningful for this name (negative enterprise value). Value it on relative multiples and Level-3 assumptions, not the raw DCF.Pre-revenue radiopharma with cash of $36.5M at 6/30/26 against ~$5.9M/quarter operating burn implies roughly 18 months of runway — under the 24-month threshold — and it must span the Actimab-A basket readout (2H:2026/1H:2027), Iomab-ACT SCD data, and the 2H:2026 cGMP plant. Burn will likely rise if registrational trials are funded, and management is candid about needing partners or additional capital; a financing is effectively required before the runway runs out.